KRAS G12R mutated cancers with co-occurring PI3K pathway mutations vs. those without PI3K pathway genetic alterations harbored significantly more SMAD4 gene defects (83.3% vs. 11.8%, P = .0034) (Supplementary Table S2). This evidence concerns the gene SMAD4 and cancer.